Sanofi and Seagen announce collaboration to develop and commercialise multiple novel antibody-drug…
The companies jointly fund and develop up to three antibody-drug conjugate programmes for the treatment of cancer
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
cancer treatment
US FDA grants priority review to Daiichi Sankyo and AstraZeneca’s sBLA of Enhertu
Enhertu is a HER2-directed Antibody Drug Conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca for treatment…
Israeli scientists find promising target for breast cancer and other cancer therapeutics
Our perception of the specific multistep molecular mechanistic process which regulates cancer initiation and progression found in…
Kite and Shoreline Biosciences enter partnership to develop novel allogeneic cell therapies
Partnership follows Kite’s investment in Shoreline’s recent Series A financing
Researchers develop technology to see inside cells
The new technology may help answer outstanding questions about the immune system, cancer, Alzheimer’s, and more
G1 Therapeutics and Genor Biopharma sign agreement for Lerociclib
As per the exclusive license agreement, Genor to lead clinical development, regulatory submissions and commercialisation of…
CSIR’s anti-cancer drug IIIM-290 goes into clinical trial
The clinical trial aims to assess safety, tolerability and exposure of the compound in humans along with the early efficacy…
Drug developers take fresh aim at ‘guided-missile’ cancer drugs
These antibody-drug conjugates, or ADCs, from companies including AztraZeneca and GlaxoSmithKline, are described by researchers as…